ArticleScientific reports2026
First insight of characteristics and prediction of Mycobacterium tuberculosis drug resistance by whole genome sequencing in Fujian Province, China.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fluoroquinolone resistance and mutation profiles inFrontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To delineate the molecular characteristics and assess the drug resistance prediction value of whole-genome sequencing (WGS) for Mycobacterium tuberculosis (MTB) in Fujian Province, China. Representative MTB surveillance isolates underwent phenotypic drug susceptibility testing (pDST), followed by WGS(gDST), with resistance mutation analysis conducted on the SAM-TB platform. The rate of mono-resistance, poly-resistance, and multidrug-resistance (MDR) identified by pDST were 38.67%, 12.00% and 10.00% respectively. Lineage analysis revealed that L2 (60.0%) and L4 (38.7%) predominated. No statistically significant difference in drug-resistance rates among lineages (χ² = 4.85, P = 0.183). Total drug resistance rate by gDST was 67.03%, harboring 126 resistance-associated mutations. The most frequent mutations were KatG S315T (22.22%), rpoB S450L (10.32%), rpsL K43R (12.70%), embB M306I (4.76%), and gyrA D94G (7.94%). Using pDST as the reference standard, the sensitivity, specificity and concordance rate of gDST to RFP, INH, FQs, EMB, SM was 78.95%, 78.05%, 76.47%, 53.85%, 45.71%, and 98.47%, 94.50%, 93.98%, 97.08%, 95.65%, and 0.81, 0.74, 0.64, 0.55, 0.48, respectively. WGS provided rapid, comprehensive genotyping of MTB isolates, revealing the predominant lineages L2 and L4 in Fujian Province and reliably predicting resistance to RFP, INH, and FQ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.